ISMP Raises Safety Concerns for 2 Novel Agents

[firemonkey]

http://www.pharmacypracticenews.com/Clinical/Article/11-17/ISMP-Raises-Safety-Concerns-for-2-Novel-Agents-/45247

The first is pimavanserin which is being tested as an adjunct therapy for schizophrenia .